

Secret Topics? Antitrust & FDI Outlook 2023

As the new year is kicking off, we lay out what is to be expected in antitrust & foreign investment control in the coming months. Natural choices are the Digital Markets Act and the presumably far-reaching amendments to German competition law. Yet, we decided to focus on **4 topics** and **3 numbers** that are not exactly secret, but might still be slightly below the usual radar:

Additional merger control regime, and more new rules. With the Foreign Subsidies Regulation, the EU has effectively introduced a new merger control regime, covering deals where parties have benefitted from foreign "financial contributions".

2023 is also set to bring other new/updated EU rules, including new guidelines for horizontal cooperations and a new market definition notice.

- 2 HR (stays) in the spotlight. Antitrust in labour markets is still very much in the focus of regulators. 2022 brought new cases (e.g., a Swiss investigation into the exchange of salary information), and we expect more to come in 2023. Compliance trainings for HR professionals are highly advisable.
- **Financial investors under scrutiny**. Financial investors should expect increased (merger control) scrutiny for "add-on" strategies, in particular in healthcare and pharma. Germany is even considering to prohibit acquisitions of medical practices by financial investors.
- 4 Supply chain due diligence and antitrust. Germany's supply chain due diligence act is now in force and obliges companies to assess and sometimes audit their suppliers. However, companies are well-advised to take into account the antitrust implications and limitations of auditing suppliers which are also competitors.

EU Phase 2 deals cleared unconditionally in 2022:

0

German Federal Cartel Office dawn raids in 2022:

18

Expected cases per year under the Foreign Subsidies Regulation:

~100

Kev contacts



Dr. Timo Angerbauer Partner

T +49 (0) 211 822 68 28 5 E timo.angerbauer@rocan.eu



Paul Drößler Partner

T +49 (0) 211 822 68 28 3 E paul.droessler@rocan.eu



Dr. Tobias Pukropski Partner

T +49 (0) 211 822 68 28 4 E tobias.pukropski@rocan.eu